A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice. [electronic resource]
Producer: 20170606Description: 1310-6 p. digitalISSN:- 1939-327X
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Autoimmune Diseases -- drug therapy
- Biomedical Research -- methods
- CD3 Complex -- chemistry
- Diabetes Mellitus, Type 1 -- drug therapy
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Immunoglobulin Fab Fragments -- administration & dosage
- Immunotherapy -- methods
- Insulin -- metabolism
- Insulin Secretion
- Insulin-Secreting Cells -- drug effects
- Interleukin-1 Receptor Accessory Protein -- antagonists & inhibitors
- Interleukin-1beta -- antagonists & inhibitors
- Mice, Inbred NOD
- Multicenter Studies as Topic
- Pilot Projects
- Receptors, Interleukin-1 Type I -- antagonists & inhibitors
- Recombinant Fusion Proteins -- therapeutic use
- Reproducibility of Results
- Research Design
- Specific Pathogen-Free Organisms
- United States
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.